Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 and BOTOX in glabellar lines
NCT06834789Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of trenibotulinumtoxinE in glabellar lines (5 cohorts), sponsored by AbbVie Inc. Primary endpoints: Adverse Events at 10.4 months and Antidrug Antibodies at 10.4 months. Started Feb 2025; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06834789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834789.